BCL9 is a Risk Factor of Neck Lymph Nodes Metastasis and Correlated with Immune Cell Infiltration in Papillary Thyroid Carcinoma
Rui Zhang,Zhengwei Gui,Jianguo Zhao,Lu Zhao
DOI: https://doi.org/10.2147/ijgm.s455846
IF: 2.145
2024-04-16
International Journal of General Medicine
Abstract:Rui Zhang, 1, &ast Zhengwei Gui, 2, &ast Jianguo Zhao, 1 Lu Zhao 2 1 Department of Thyroid and Breast Surgery, Wuhan No. 1 Hospital, Wuhan, 430030, People's Republic of China; 2 Department of Thyroid and Breast Surgery, Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lu Zhao, Department of Thyroid and Breast Surgery, Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, No. 1095 of Jiefang Avenue, Wuhan, 430030, People's Republic of China, Email Purpose: B-cell lymphoma 9 (BCL9), a key transcription co-activator of the Wnt pathway, contributed to tumor progression and metastasis in various tumors, whereas, the role of BCL9 in papillary thyroid cancer (PTC) has not been investigated. Methods: We acquired PTC gene expression data from The Cancer Genome Atlas (TCGA) database. Fifty-nine PTC tissues were applied to validate the clinical significance of BCL9. Cell experiments were applied to investigate the role of BCL9. Bioinformatics analysis was employed to investigate the biological functions of BCL9. Results: We found that BCL9 was higher expressed ( P < 0.05) and an independent risk factor for lymph node metastasis ( OR = 3.770, P = 0.025), as well as associated with poorer progression-free survival (PFS) ( P = 0.049) in PTC. BCL9 knockdown inhibited proliferation and invasion of PTC cells. BCL9 was positively associated with the key genes of Wnt/β-catenin and MAPK pathway by co-expression analysis. GO, KEGG and GSEA analysis showed BCL9 might participated in PPAR, cAMP, and focal adhesion pathway. CIBERSORT analysis found BCL9 was negatively associated with CD8+ T cells and NK cell infiltration and positively with PD-L1 expression. Conclusion: Therefore, BCL9 was associated with lymph node metastasis and shorter PFS of PTC, due to promotion of PTC cell proliferation and invasion, activation of Wnt/β-catenin and MAPK pathway, inhibition of CD8+ T and NK cell infiltration, and promotion of PD-L1 expression. Keywords: BCL9, papillary thyroid cancer, lymph node metastasis, tumor immune microenvironment, tumor-infiltrating immune cells Thyroid cancer (TC) is the endocrine malignant tumor with the highest incidence rate. Eighty-five percent of all thyroid cancer subtypes are papillary thyroid cancer (PTC), with a growing incidence rate every year, especially in developed countries. 1 Due to the widely applied ultrasonography in the early diagnosis of TC, most patients with PTC have a relatively satisfactory clinical prognosis followed the standard surgery therapy and thyroid stimulating hormone (TSH) inhibition or radioactive iodine. 2 However, nearly 50% PTC patients still face a presence of an approximately 30% recurrence rate and 8.6% mortality for a three-decade period, 3 and either thyroid ultrasonography or FNAC sometimes provides indeterminate reports which cause difficulties in interpretation and clinical management. 4 Therefore, it is extraordinarily significant to uncover promising prognostic markers for PTC patients to early screening, timely treatment, effective monitoring and prolonged survival time. Wnt/β-catenin pathway is involved in many key aspects of cancer development, 5 including in thyroid carcinoma. 6,7 The progression and metastatic activities of PTC have been verified to be correlated with the downregulation of E-cadherin and the cytoplasmic accumulation of β-catenin. 8 Furthermore, nuclear β-catenin can induce the expression of B-cell lymphoma 9 (BCL9) and B-cell lymphoma 9-like (BCL9L), which inducing tumor proliferation and survival. 9 BCL9 protein coded by BCL9 gene which located on chromosome 1q21 often involved in secondary chromosomal abnormalities, which connect ygopus and β-catenin 10 is absent expressed normal tissues, 11 and the overexpression of BCL9 contributes to the tumor proliferation, recurrence, progression, and metastasis in colorectal cancer, multiple myeloma, hepatocellular carcinoma and breast cancer, and BCL9 knockdown can effectively increase the survival of xenograft mice. 12–14 This evidence confirms the involvement of BCL9 in tumor progression, underscoring its relevance as a new therapeutic target for cancers associated with Wnt activation. However, the value of BCL9 and the molecular mechanism of action of BCL9 in PTC have not been studied. In this study, we explored the expression, prognostic value, and mechanism of -Abstract Truncated-
medicine, general & internal